Clinical and brain SPECT scan response to zolpidem in patients after brain damage

Abstract

Previous reports document transient improvements after daily zolpidem (CAS 82626-48-0) in patients with brain damage. This multi-patient study evaluates the response to zolpidem in neurologically disabled patients, using ^99m TcHMPAO brain SPECT scans and clinical rating scales.

Method:

23 of 41 consecutive adult patients, at least 6 months after brain damage were identified as neurologically disabled patients by scoring less than 100/100 on the Barthel Index. Causes of their brain damage included stroke (n = 12), traumatic brain injury (n = 7), anaphylaxis (n = 2), drugs overdose (n = 1) and birth injury (n = 1). The selected 23 patients had a baseline ^99m TcHMPAO brain SPECT scan before starting daily zolpidem therapy and a second within two weeks of therapy, performed 1 h after 10 mg oral zolpidem. Scans were designated as improved when at least two of three assessors detected improvement after zolpidem. The rest were designated non improved. After four months daily zolpidem therapy, patients were rated on the Tinetti Falls Efficacy Scale (TFES) before and after zolpidem. The TFES ratings were compared using a Wilcoxon non parametric signed rank test. Scan improvers were compared with non improvers, using a two sample t test with unequal variance.

Results:

Mean overall improvement after zolpidem on TFES was 11.3%, from 73.4/100 to 62.1/100 (p = 0.0001). 10/23 (43%) patients improved on SPECT scan after zolpidem. Their mean TFES improvement was 19.4% (±16.75) compared with 5.08% (±5.17) in 13/23 non improvers (p = 0.0081).

Conclusion:

This prospective study adds further evidence to previous reports of zolpidem efficacy in patients with established brain damage.

Key words

CAS 82626-48-0 - Clinical rating scale - SPECT - Stroke - Traumatic brain injury - Zolpidem

• Literature

• 1 Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs. 2005; 19 (1) 65-89
• 2 Sanger DJ, Zirkovic B. The discrimination stimulus properties of zolpidem, a novel imidazopyridine hypnotic. Psychopharmacology. 1986; 89 (3) 317-22
• 3 Sanger DJ, Griebel G, Perrault G, Clausne Y, Schoemaker H. Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity. Pharmacol Biochem Behav. 1999; 64 (2) 269-73
• 4 Clauss RP, Güldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR. Extraordinary arousal from semicomatose state on zolpidem. SAfr Med J. 2000; 90 (1) 68-72
• 5 Clauss RP, Nel HW. Drug induced arousal from permanent vegetative state. NeuroRehabilitation. 2006; 21 (1) 23-8
• 6 Brefel-Courbon C, Payoux P, Ory F, Sommet A, Slaoui T, Raboyeau G et al Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy. Ann Neurol. 2007; 62 (1) 102
• 7 Cohen SI, Duong TT. Increased arousal in a Patient with anoxic brain injury after administration of zolpidem. Am J Phys Med Rehabil. 2008; 87 (3) 229-31
• 8 Shames JL, Ring H. Transient reversal of anoxic brain injury-related minimally conscious state after zolpidem administration: a case report. Arch Phys Med Rehabil. 2008; 89: 386-8
• 9 Clauss RP, Sathekge MM, Nel HW. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med. 2004; 351: 511-12
• 10 Clauss RP, Jayarajan V, Nel HW, Saunders E. Evidence for zolpidem efficacy in auditory impairment. 9th European Federation of Neurological Societies Congress 2005 Athens, Greece, September 7–20.
• 11 Cohen L, Chaaban B, Haberl MO. Transient improvement of aphasia with zolpidem. N Engl J Med. 2004; 350 (9) 949-50
• 12 Shadan FF, Poceta JS, Kline LE. zolpidem for postanoxic spasticity. Southern Med J. 2004; 97 (8) 791-92
• 13 Clauss RP, Dormehl IC, Oliver DW, Nel HW, Kilian E, Louw WK. Measurement of cerebral perfusion after zolpidem administration in the baboon. Arzneimittelforschung. 2001; 51 (8) 619-22
• 14 Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965; 14: 56-61
• 15 Tinetti ME, Richman D, Powell L. Falls Efficacy as a Measure of Fear of Falling. J Gerontol Psychol Sci. 1990; 45 (6) 239-43
• 16 Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982; 37: 122-47
• 17 Hall SD, Yamawaki N, Fisher AE, Clauss RP, Woodhall GL, Stanford IM. Desynchronization of pathological low-frequency brain activity by the hypnotic drug zolpidem. Nature Precedings 2008 hdl:10101/npre.2008.1966.1
• 18 Clauss RP, Dormehl IC, Kilian E, Oliver DW, Nel HW, Louw WKA. Cerebral blood perfusion after treatment with omega receptor drugs, zolpidem and flumazenil in the baboon. Arzneimittelforschung. 2002; 52: 740-4
• 19 Slomka PJ, Radau PE, Hurwitz G, Dey D. Automated three-dimensional quantification of myocardial perfusion and brain SPECT. Comput Med Imaging Graph. 2001; 25: 153-64
• 20 Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1965; 2: 165-89
• 21 Van KLaere, Koole M, Versijpt J, Dierckx R. Non-uniform versus uniform attenuation correction in brain perfusion SPET of healthy volunteers. Eur J Nucl Med. 2001; 28: 90-8
• 22 Van KLaere, Warwick J, Versijpt J, Goethals I, Audenaert K, Van BHeerden et al Analysis of clinical brain SPECT data based on anatomic standardization and referente to normal data: an ROC-based comparison of visual, semiquantitative and voxel-based methods. J Nucl Med. 2002; 43 (4) 458-69